China’s National Anti-Tumor Drug Surveillance System (NATDSS) is the country’s largest real-world oncology network, aggregating records from 1,400+ hospitals and over 15M cancer patients since 2013. Overseen by the National Cancer Center, it enhances cancer diagnosis, treatment, and follow-up through pan-tumor data, geographic diversity, and centralized ethics approvals that simplify collaborations. NATDSS integrates EMR data, mortality linkage with the CDC, and captures patient demographics, tumor characteristics, treatments, outcomes, and resource use. Applications span safety and epidemiology, HEOR, insight generation, and trial planning, making it a cornerstone for oncology RWE and evidence-based care in China.

Join for free to read